Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy

  • Koshi Yamada
  • , Zhi Qiang Huang
  • , Milan Raska
  • , Colin Reily
  • , Joshua C. Anderson
  • , Hitoshi Suzuki
  • , Hiroyuki Ueda
  • , Zina Moldoveanu
  • , Krzysztof Kiryluk
  • , Yusuke Suzuki
  • , Robert J. Wyatt
  • , Yasuhiko Tomino
  • , Ali G. Gharavi
  • , Amy Weinmann
  • , Bruce A. Julian
  • , Christopher D. Willey
  • , Jan Novak

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Abstract

Introduction IgA nephropathy is a chronic renal disease characterized by mesangial immunodeposits that contain autoantigen, which is aberrantly glycosylated IgA1 with some hinge-region O-glycans deficient in galactose. Macroscopic hematuria during an upper respiratory tract infection is common among patients with IgA nephropathy, which suggests a connection between inflammation and disease activity. Interleukin-6 (IL-6) is an inflammatory cytokine involved in IgA immune response. We previously showed that IL-6 selectively increases production of galactose-deficient IgA1 in IgA1-secreting cells from patients with IgA nephropathy. Methods We characterized IL-6 signaling pathways involved in the overproduction of galactose-deficient IgA1. To understand molecular mechanisms, IL-6 signaling was analyzed by kinomic activity profiling and Western blotting, followed by confirmation assays using siRNA knock-down and small-molecule inhibitors. Results STAT3 was differentially activated by IL-6 in IgA1-secreting cells from patients with IgA nephropathy compared with those from healthy control subjects. Specifically, IL-6 induced enhanced and prolonged phosphorylation of STAT3 in the cells from patients with IgA nephropathy, which resulted in overproduction of galactose-deficient IgA1. This IL-6−mediated overproduction of galactose-deficient IgA1 could be blocked by small molecule inhibitors of JAK/STAT signaling. Discussion Our results revealed that IL-6−induced aberrant activation of STAT3-mediated overproduction of galactose-deficient IgA1. STAT3 signaling pathway may thus represent a new target for disease-specific therapy of IgA nephropathy.

Original languageEnglish
Pages (from-to)1194-1207
Number of pages14
JournalKidney International Reports
Volume2
Issue number6
DOIs
StatePublished - 2017
Externally publishedYes

Keywords

  • IgA nephropathy
  • IgA1
  • O-glycans
  • aberrant glycosylation
  • autoantigen

Fingerprint

Dive into the research topics of 'Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy'. Together they form a unique fingerprint.

Cite this